A number of other equities analysts have also commented on AZN. Finally, Credit Suisse Group raised their price objective on AstraZeneca from GBX 8,200 ($107.87) to GBX 8,500 ($111.81) and gave the stock an “outperform” rating in a research note on Thursday, January 16th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. AstraZeneca presently has an average rating of “Buy” and an average price target of GBX 7,912.14 ($104.08). AstraZeneca stock opened at GBX 7,300 ($96.03) on Friday. The stock’s fifty day moving average price is GBX 7,666.44 and its two-hundred day moving average price is GBX 7,335.03. AstraZeneca has a one year low of GBX 109.51 ($1.44) and a one year high of GBX 8,227.88 ($108.23).
1 other references
Latest Stories From Referenced Companies
Apr 05, 2020
Apr 04, 2020